Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

被引:8
|
作者
Sanchez Hernandez, Alfredo [1 ]
Jose Juan, Oscar [2 ]
Vidal Martinez, Jose [3 ]
Blanco, Remei [4 ]
Macia, Sonia [5 ]
Esquerdo Galiana, Gaspar [6 ]
Aparisi Aparisi, Francisco [7 ]
Garde Noguera, Javier [8 ]
Catot, Silvia [9 ]
Losa Gaspa, Ferran [10 ]
Garcia-Pinon, Francisco [11 ]
机构
[1] Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12003, Spain
[2] Hosp Univ & Politecn La Fe, Med Oncol Serv, Valencia, Spain
[3] Hosp Arnau Vilanova, Serv Anal Clin, Valencia 46015, Spain
[4] Hosp Mutua de Terrassa, Med Oncol Serv, Barcelona 08221, Spain
[5] Hosp Gen Elda, Med Oncol Serv, Alicante 03600, Spain
[6] Clin Benidorm, Med Oncol Serv, Alicante 03501, Spain
[7] Hosp Virgen de los Lirios, Med Oncol Serv, Alicante 03804, Spain
[8] Hosp Arnau Vilanova, Med Oncol Serv, Valencia 46015, Spain
[9] Clin Althaia de Manresa, Med Oncol Serv, Barcelona 08243, Spain
[10] Hosp St Joan dEspi Moises Broggi, Med Oncol Serv, Barcelona 08970, Spain
[11] Hosp Prov Castellon, Fdn Comunidad Valenciana, Castellon de La Plana 12003, Spain
关键词
Circulating endothelial cell; NSCLC; Chemotherapy; PACLITAXEL-CARBOPLATIN; PERIPHERAL-BLOOD; SURROGATE MARKER; CLINICAL-VALUE; CANCER; ANGIOGENESIS; BEVACIZUMAB; PROGENITORS; CISPLATIN; SURVIVAL;
D O I
10.1007/s12094-014-1223-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). A prospective study was performed whose main objective was to study whether the numbers of CEC at baseline and prior to the second and third cycle of chemotherapy were response predictors. Sixty-nine patients received cisplatin plus pemetrexed, and peripheral blood samples were performed at baseline and after second and third cycle. Separation and CEC count were performed using inmunomagnetic separation (CellSearch). The CEC count in 4 mL of peripheral blood was obtained prior to the first, second, and third cycle of treatment. Baseline levels and evolution of CEC were correlated with response to treatment according to RECIST criteria after three cycles of treatment. Sixty-nine patients were included: 43 (64.2 %) received cisplatin/pemetrexed and 24 (35.8 %) carboplatin/pemetrexed. Range of baseline CEC: 8-965 (mean of 153 cel/4 mL). The results after 3 cycles were: 25 partial responses (36.2 %), 17 cases of stabilization of disease (24.6 %), 16 of progressive disease (23.2 %) and 11 non-evaluables (16 %). No significant relationship between the baseline CEC count and response was found (p value = 0.831). Increase > 50 % between the first and second cycle was correlated significantly with progression disease (p = 0.008). Patients who had a baseline CEC count greater than the mean (> 153 cells/4 mL) showed longer progression-free survival and global survival without statistical significance. In this homogeneous group of patients with NSCLC, there is no correlation between response to treatment and CEC baseline levels. The increase in CEC numbers after the first cycle could be a negative predictive factor.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 50 条
  • [1] Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma
    Alfredo Sánchez Hernández
    Oscar José Juan
    José Vidal Martínez
    Remei Blanco
    Sonia Maciá
    Gaspar Esquerdo Galiana
    Francisco Aparisi aparisi
    Javier Garde Noguera
    Silvia Catot
    Ferran Losa Gaspá
    Francisco García-Piñon
    Clinical and Translational Oncology, 2015, 17 : 281 - 288
  • [2] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [3] A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer
    Yu, Hui
    Zhang, Jian
    Wu, Xianghua
    Luo, Zhiguo
    Wang, Huijie
    Sun, Si
    Peng, Wei
    Qiao, Jie
    Feng, Yu
    Wang, Jialei
    Chang, Jianhua
    CANCER BIOLOGY & THERAPY, 2014, 15 (07) : 832 - 839
  • [4] Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy
    Najjar, Fadi
    Alammar, Moosheer
    Bachour, Marroan
    Almalla, Nissreen
    Altahan, Moaz
    Alali, Ali
    Al-Massarani, Ghassan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (01) : 119 - 125
  • [5] Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
    Kwok, Wang Chun
    Chiang, Ka Yan
    Ho, James Chung Man
    Lam, David Chi Leung
    Ip, Mary Sau Man
    Tam, Terence Chi Chun
    LUNG CANCER, 2021, 162 : 169 - 174
  • [6] Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
    Lal, R.
    Hillerdal, G. N.
    Shah, R. N. H.
    Crosse, B.
    Thompson, J.
    Nicolson, M.
    Vikstrom, A.
    Potter, V. A.
    Visseren-Grul, C.
    Lorenzo, M.
    D'yachkova, Y.
    Bourayou, N.
    Summers, Y. J.
    LUNG CANCER, 2015, 89 (02) : 154 - 160
  • [7] Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab
    Sudo, Kazuhisa
    Sato, Kazuhiro
    Sakamoto, Sho
    Hasegawa, Yukiyasu
    Asano, Mariko
    Okuda, Yuji
    Takeda, Masahide
    Sano, Masaaki
    Watanabe, Hiroyuki
    Shioya, Takanobu
    Ito, Hiroshi
    ANTICANCER RESEARCH, 2017, 37 (10) : 5565 - 5571
  • [8] Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel
    Kawaishi, Makoto
    Fujiwara, Yutaka
    Fukui, Tomoya
    Kato, Terufumi
    Yamada, Kazuhiko
    Ohe, Yuichiro
    Kunitoh, Hideo
    Sekine, Ikuo
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Watabe, Takeshi
    Shimoda, Yuji
    Arao, Tokuzo
    Nishio, Kazuto
    Tamura, Tomohide
    Koizumi, Fumiaki
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 208 - 213
  • [9] Pemetrexed and Cisplatin for Advanced Non-squamous Non-small Cell Lung Cancer in Japanese Patients: Phase II Study
    Kawano, Yuko
    Ohyanagi, Fumiyoshi
    Yanagitani, Noriko
    Kudo, Keita
    Horiike, Atsushi
    Tanimoto, Azusa
    Nishizawa, Hironari
    Ichikawa, Atsuo
    Sakatani, Toshio
    Nakatomi, Katsumi
    Hagiwara, Sachiko
    Ninomiya, Hironori
    Motoi, Noriko
    Ishikawa, Yuichi
    Horai, Takeshi
    Nishio, Makoto
    ANTICANCER RESEARCH, 2013, 33 (08) : 3327 - 3333
  • [10] Pemetrexed A Review of its Use in the Management of Advanced Non-Squamous Non-Small Cell Lung Cancer
    Baldwin, Claudine M.
    Perry, Caroline M.
    DRUGS, 2009, 69 (16) : 2279 - 2302